Paul Tudor Jones Igm Biosciences, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.51 - $11.47 $94,635 - $166,739	14,537 New	14,537 $99,000
Q3 2023 Nov 15, 2023	BUY	$6.66 - $10.64 $20,945 - $33,462	3,145 Added 27.73%	14,486 $120,000
Q2 2023 Aug 14, 2023	SELL	$8.86 - $14.0 $27,962 - $44,184	-3,156 Reduced 21.77%	11,341 $104,000
Q1 2023 May 15, 2023	BUY	$13.74 - $25.76 $199,188 - $373,442	14,497 New	14,497 $199,000
Q2 2022 Aug 15, 2022	SELL	$13.27 - $25.5 $194,259 - $373,294	-14,639 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $196,455 - $435,217	14,639 New	14,639 $391,000
Q1 2021 May 17, 2021	SELL	$71.56 - $121.23 $263,555 - $446,490	-3,683 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$47.41 - $115.03 $174,611 - $423,655	3,683 New	3,683 $325,000

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $200M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.